Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs. The company is set to capture 50% of the $95 billion obesity market by 2050.

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs. The company is set to capture 50% of the $95 billion obesity market by 2050. We got a glimpse into Eli ...

The pharma major is also strengthening its presence in the central nervous system (CNS) therapeutic area, Vohra stated ...